foxo4-dri senolytic human trial Results: What to Expect (2026) FOXO4-DRI alleviates age-related testosterone secretion

Our commitment to transparency includes publication of assay results, purity verification, identity confirmation, endotoxin testing, microbial screening, elemental impurity analysis and molecular mass verification

Shortening the interval between injections brought about sustained symptoms of supraphysiological markers of excess free testosterone, oestradiol and dihydrotestosterone

The result is that improvements in gut symptom burden, mucosal integrity, and post-meal function often begin within the first 7 to 14 days of the protocol

Why it matters: For patients with chronic joint pain, tendonitis, gut inflammation, or post-surgical inflammation, this means less swelling, better circulation, and faster repair